ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 762.3 USD | -1.20% |
|
+3.63% | +30.66% |
| 07:42pm | Roughly 1 in 8 US adults have taken GLP-1 drugs like Wegovy, poll shows | RE |
| 11:20am | India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
771.6
USD
Average target price
850.4
USD
Spread / Average Target
+10.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.66% | 695B | |
| +26.51% | 568B | |
| -4.61% | 361B | |
| +19.69% | 330B | |
| +3.82% | 283B | |
| +16.70% | 239B | |
| +8.78% | 204B | |
| -7.93% | 198B | |
| +8.08% | 168B | |
| +5.09% | 125B |
- Stock Market
- Equities
- LLY Stock
- News Eli Lilly and Company
- Eli Lilly Calls for Regulatory Scrutiny of Novo Holding's Catalent Deal
